PF-06952229

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NamePF-06952229
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta receptor 1 inhibitors
TargetsTransforming growth factor beta receptor 1
Therapy Area/IndicationsProstatic NeoplasmsPancreatic NeoplasmsLiver Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsPancreatic NeoplasmsLiver Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A